ReviewJournal of clinical microbiology2012
Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.
Review in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 245 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
245 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence and trends of fluconazole resistance in non-albicans Candida species: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants.The Journal of antimicrobial chemotherapy · 2018Trial
- [Rapid detection of fluconazole resistance inNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Voriconazole Activity AgainstMolecules (Basel, Switzerland) · 2026Article
- In Vitro Antifungal Drug Susceptibility of Feline Sporothrix schenckii Complex Isolates, Thailand, 2023-2025.Emerging infectious diseases · 2026Article
- Evaluation of Curcumin inPharmaceuticals (Basel, Switzerland) · 2026Article
- Shifting Epidemiology and Antifungal Susceptibility Patterns of Clinical Fungal Isolates in an Intensive Care Unit (ICU) from Bucharest, Romania: A Retrospective Observational Study.Antibiotics (Basel, Switzerland) · 2026Article
- Antifungal Effects of Terminalia arjuna Fruit Extract on Multidrug-Resistant Candida auris: An In Vitro Study.Cureus · 2026Article
- Ethanol production from rice straw: Comparative study of single and combined use of CaO/Ag nanocatalyst with Saccharomyces cerevisiae and Aspergillus terreus.World journal of microbiology & biotechnology · 2026Article
- Article
- Candiduria in catheterized ICU patients: epidemiology, molecular identification, and antifungal susceptibility.Iranian journal of microbiology · 2026Article
- Identification ofMicrobiology spectrum · 2026Article
- Nine-Year Surveillance of Candida Bloodstream Infections in a Southern Italian Tertiary Hospital: Species Distribution, Antifungal Resistance, and Stewardship Implications.Journal of personalized medicine · 2026Article
- Antifungal Susceptibility of Rare Yeasts Causing Vulvovaginal Candidiasis in the Acidic Vaginal Environment.Infection and drug resistance · 2026Article
- Fungal keratitis: Does antifungal Resistance Influence the outcome?International ophthalmology · 2025Article
- Trends in Pediatric Invasive Candidiasis: Shifting Species Distribution and Improving Outcomes.Mycopathologia · 2025Article
- Antifungal Drug Efficacy Profiles Against VaginalJournal of clinical medicine · 2025Article
- Candidemia due toMedical mycology case reports · 2025Article
- Fabrication of a sponge-like protein based hydrogel incorporating fluconazole against Candida species as a potential treatment for vulvovaginal candidiasis infection.Scientific reports · 2025Article
- Article
185 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antifungal susceptibility testing of Candida has been standardized and refined and now may play a useful role in managing Candida infections. Important new developments include validation of 24-h reading times for all antifungal agents and the establishment of species-specific epidemiological cutoff values (ECVs) for the systemically active antifungal agents and both common and uncommon species of Candida. The clinical breakpoints (CBPs) for fluconazole, voriconazole, and the echinocandins have been revised to provide species-specific interpretive criteria for the six most common species. The revised CBPs not only are predictive of clinical outcome but also provide a more sensitive means of identifying those strains with acquired or mutational resistance mechanisms. This brief review serves as an update on the new developments in the antifungal susceptibility testing of Candida spp. using Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BMD) methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.